Pyrukynd

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

mitapivat sulfate

Available from:

Agios Netherlands B.V.

ATC code:

B06AX04

INN (International Name):

mitapivat

Therapeutic group:

Other hematological agents

Therapeutic area:

Genetic Diseases, Inborn; Anemia, Hemolytic

Therapeutic indications:

Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.

Authorization status:

Awtorizzat

Authorization date:

2022-11-09

Patient Information leaflet

                                57
B. FULJETT TA’ TAGĦRIF
58
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
PYRUKYND 5 MG PILLOLI MIKSIJA B’RITA
PYRUKYND 20 MG PILLOLI MIKSIJA B’RITA
PYRUKYND 50 MG PILLOLI MIKSIJA B’RITA
mitapivat
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan ser jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar
is-sigurtà. Inti tista’ tgħin billi tirrapporta
kwalunkwe effett sekondarju li jista’ jkollok. Ara t-tmiem ta’
sezzjoni 4 biex tara kif għandek
tirrapporta effetti sekondarji.
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
–
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
–
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib, lill-ispiżjar jew
lill-infermier tiegħek.
–
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara anke jekk għandhom l-istess sinjali ta’ mard
bħal tiegħek.
–
Jekk ikollok xi effett sekondarju, kellem lit-tabib, lill-ispiżjar
jew lill-infermier tiegħek. Dan
jinkludi xi effett sekondarju possibbli li mhuwiex elenkat f’dan
il-fuljett. Ara sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Pyrukynd u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Pyrukynd
3.
Kif għandek tieħu Pyrukynd
4.
Effetti sekondarji possibbli
5.
Kif taħżen Pyrukynd
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU PYRUKYND U GĦALXIEX JINTUŻA
Pyrukynd fih is-sustanza attiva mitapivat.
Pyrukynd jintuża għat-trattament ta’ adulti b’kundizzjoni li
tintiret imsejħa nuqqas ta’ pyruvate kinase.
Pazjenti li għandhom nuqqas ta’ pyruvate kinase ikollhom bidliet
f’enzima fiċ-ċelloli ħomor tad-demm
tagħhom imsejħa pyruvate kinase, li jwasslu biex din ma taħdimx
sew. Dan iwassal biex iċ-ċelloli
ħomor tad-demm jitkissru malajr wisq, proċess magħruf bħala
anemija emolitika.
Pyrukynd jgħin lill-enzima pyruvate kinase taħdem aħjar. Iżid
l-enerġija fiċ
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan ser jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar
is-sigurtà. Il-professjonisti tal-kura tas-saħħa
huma mitluba jirrappurtaw kwalunkwe reazzjoni avversa suspettata. Ara
sezzjoni 4.8 dwar kif
għandhom jiġu rappurtati reazzjonijiet avversi.
1.
ISEM IL-PRODOTT MEDIĊINALI
Pyrukynd 5 mg pilloli miksija b’rita
Pyrukynd 20 mg pilloli miksija b’rita
Pyrukynd 50 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Pyrukynd 5 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 5 mg ta’ mitapivat (bħala
sulfate).
_Eċċipjent b’effett magħruf _
Kull pillola miksija b’rita fiha 0.3 mg ta’ lactose (bħala
monohydrate).
Pyrukynd 20 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 20 mg ta’ mitapivat (bħala
sulfate).
_Eċċipjent b’effett magħruf _
Kull pillola miksija b’rita fiha 1.4 mg ta’ lactose (bħala
monohydrate).
Pyrukynd 50 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 50 mg ta’ mitapivat (bħala
sulfate).
_Eċċipjent b’effett magħruf _
Kull pillola miksija b’rita fiha 3.4 mg ta’ lactose (bħala
monohydrate).
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita
Pyrukynd 5 mg pilloli miksija b’rita
Pilloli miksija b’rita tondi ta’ kulur blu b’dijametru ta’
madwar 5 mm, b’“M5” stampata b’linka sewda
fuq naħa u xejn fuq in-naħa l-oħra.
Pyrukynd 20 mg pilloli miksija b’rita
Pilloli miksija b’rita tondi ta’ kulur blu b’dijametru ta’
madwar 8 mm, b’“M20” stampata b’linka
sewda fuq naħa u xejn fuq in-naħa l-oħra.
Pyrukynd 50 mg pilloli miksija b’rita
Pilloli miksija b’rita ta’ għamla tawwalija u ta’ kulur blu
b’daqs ta’ madwar 16 mm x 6.8 mm,
b’“M50” stampata b’linka sewda fuq naħa u xejn fuq in-naħa
l-oħra.
3
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TER
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 05-12-2022
Public Assessment Report Public Assessment Report Bulgarian 05-12-2022
Patient Information leaflet Patient Information leaflet Spanish 05-12-2022
Public Assessment Report Public Assessment Report Spanish 05-12-2022
Patient Information leaflet Patient Information leaflet Czech 05-12-2022
Public Assessment Report Public Assessment Report Czech 05-12-2022
Patient Information leaflet Patient Information leaflet Danish 05-12-2022
Public Assessment Report Public Assessment Report Danish 05-12-2022
Patient Information leaflet Patient Information leaflet German 05-12-2022
Public Assessment Report Public Assessment Report German 05-12-2022
Patient Information leaflet Patient Information leaflet Estonian 05-12-2022
Public Assessment Report Public Assessment Report Estonian 05-12-2022
Patient Information leaflet Patient Information leaflet Greek 05-12-2022
Public Assessment Report Public Assessment Report Greek 05-12-2022
Patient Information leaflet Patient Information leaflet English 05-12-2022
Public Assessment Report Public Assessment Report English 05-12-2022
Patient Information leaflet Patient Information leaflet French 05-12-2022
Public Assessment Report Public Assessment Report French 05-12-2022
Patient Information leaflet Patient Information leaflet Italian 05-12-2022
Public Assessment Report Public Assessment Report Italian 05-12-2022
Patient Information leaflet Patient Information leaflet Latvian 05-12-2022
Public Assessment Report Public Assessment Report Latvian 05-12-2022
Patient Information leaflet Patient Information leaflet Lithuanian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 05-12-2022
Public Assessment Report Public Assessment Report Lithuanian 05-12-2022
Patient Information leaflet Patient Information leaflet Hungarian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 05-12-2022
Public Assessment Report Public Assessment Report Hungarian 05-12-2022
Patient Information leaflet Patient Information leaflet Dutch 05-12-2022
Public Assessment Report Public Assessment Report Dutch 05-12-2022
Patient Information leaflet Patient Information leaflet Polish 05-12-2022
Public Assessment Report Public Assessment Report Polish 05-12-2022
Patient Information leaflet Patient Information leaflet Portuguese 05-12-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 05-12-2022
Public Assessment Report Public Assessment Report Portuguese 05-12-2022
Patient Information leaflet Patient Information leaflet Romanian 05-12-2022
Public Assessment Report Public Assessment Report Romanian 05-12-2022
Patient Information leaflet Patient Information leaflet Slovak 05-12-2022
Public Assessment Report Public Assessment Report Slovak 05-12-2022
Patient Information leaflet Patient Information leaflet Slovenian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 05-12-2022
Public Assessment Report Public Assessment Report Slovenian 05-12-2022
Patient Information leaflet Patient Information leaflet Finnish 05-12-2022
Public Assessment Report Public Assessment Report Finnish 05-12-2022
Patient Information leaflet Patient Information leaflet Swedish 05-12-2022
Public Assessment Report Public Assessment Report Swedish 05-12-2022
Patient Information leaflet Patient Information leaflet Norwegian 05-12-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 05-12-2022
Patient Information leaflet Patient Information leaflet Icelandic 05-12-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 05-12-2022
Patient Information leaflet Patient Information leaflet Croatian 05-12-2022
Public Assessment Report Public Assessment Report Croatian 05-12-2022
Patient Information leaflet Patient Information leaflet Irish 05-12-2022

Search alerts related to this product

View documents history